Katelyn Baker
Well-Known Member
It has been more than a year since Jonathan Zaid won the right to have his medical marijuana prescription covered under his group benefits plan, effectively kicking off a wider conversation about coverage for the drug.
For nearly a decade, Zaid, 23, had been suffering from a chronic condition called new daily persistent headaches. He tried a variety of prescription medications and alternative treatments, but nothing really worked. "I turned to medical cannabis after I learned that it could work for my condition and it was really working well, but the cost started adding up," he says, noting his monthly out-ofpocket costs for vaporizing the drug were averaging about $800.
Zaid's benefits had covered the other prescription drugs and treatments he had tried to relieve his pain, whether they were through his father's employer-paid plan or his undergraduate health coverage at the University of Waterloo. He had even obtained quick approval for a few medications that weren't on the formulary.
"I approached the school to do the same thing with medical cannabis, but this time, it ended up being an eightmonth process of talking with the student union, lots of meetings and conversations about medical cannabis and its use, a lot of education," he says.
"In the end, they determined it would have a positive impact on both my health and my education, so the school decided to cover it."
Zaid is the founder and executive director of a group called Canadians for Fair Access to Medical Marijuana. "I am helping a lot of people through CFAMM's individualized insurance education program," he says.
"Patients are reaching out to their employers and to their group plan administrators to try to get coverage, and I think more and more employers are responding. We're just going through that process with a lot of them now. It's really a long process and people react with misconceptions surrounding it at first, so there's a lot of education needed in most cases."
Chris Murray, director of medical development at Bedrocan Canada Inc., one of nearly 30 licensed producers in Canada, says the body of evidence for the benefits of medical marijuana is growing and researchers are looking at cannabis more regularly now than they were a few decades ago. The company is working with Zaid to identify people who may be eligible for insurance based on their existing group benefits plans.
"We believe there are hundreds, if not thousands, of other Jonathans out there who just need the right guidance," he says. "Our hope is that a hands-on approach will create momentum and ultimately lead to system-wide changes."
If there are others like Zaid out there, plan sponsors will want to pay attention as there's a chance one of them works for their company. And with drug costs continuing to escalate and companies like Shoppers Drug Mart exploring the possibility of getting into the sale of medical marijuana, employers will want to keep an eye on this issue.
Keeping it legal
The legislative landscape around medical marijuana in Canada has changed dramatically in recent years. Canada is still dealing with the fallout of the most recent significant change that began in June 2013 when the marijuana for medical purposes regulations came into effect. The regulations, which allow licensed producers to grow and distribute medical marijuana, have been subject to numerous legal challenges, with the court recently having declared them invalid.
On the topic of legalizing marijuana for recreational purposes, federal Health Minister Jane Philpott announced in April the government would introduce legislation next year. "The election of the Liberal majority government in October and the legalization narrative was an enormous change in the equation," says Mike Sullivan, president of Cubic Health Inc.
"But with the recent decision by the appeals court that effectively suggested the new regulations are not appropriate, there was a messaging back saying that the new regulations implemented by the Conservative government don't work and they need to be fixed.
"It has left things in an enormous mess, and I don't think anybody knows what's going to happen now until the regulations get redrafted and recreated. [Legalization] is very much akin to something becoming over the counter in the prescription drug benefit world. If it becomes an over-the-counter product, why does anybody go through the process of obtaining a prescription and having it run through as a prescription?"
Another legislative issue that could affect employers is around discrimination, according to Will Cascadden, a partner at McCarthy Tétrault LLP's Calgary office.
"If a doctor tells an employee their illness requires treatment to be the use of medical marijuana in some form - and that's the medical prescription - and the employee says, 'If I needed insulin, it would be covered, but because I need medical marijuana, it isn't,' that could be discriminating against someone on the basis of illness or disability. "If group benefit plans don't cover it, I can see there being a challenge from a human rights' perspective. Ultimately, the humans rights [tribunals] will say it is discriminatory to not cover that medication, when you cover others, because that particular disability is the one a person has and if they're not getting the same treatment, that's discriminatory."
But the first step will have to be sorting out the regulatory regime, and then the pharmaceutical industry and benefits providers will have to figure out how to deal with it, he says. "At that point, there will be a process."
'Uptick in claims'
It's becoming more and more common for doctors to prescribe medical marijuana to people with certain types of cancer, HIV/AIDS, Crohn's disease and multiple sclerosis, as well as for chronic pain and as a sleep aid or a replacement for potentially expensive and harmful opioid treatments.
"Why are certain drugs covered and others not covered?" asks Robert Crowder, president of the Benefits Trust. "It's a real question that employers are battling with and it's becoming a bigger and bigger issue as the benefits of medical marijuana are becoming more and more relevant on a case-by-case basis."
While there are about 30 companies with licences to produce and sell medical marijuana in Canada, Health Canada hasn't provided it with a drug identification number. But the Canada Revenue Agency did add it as a medically exempt tax credit at the end of 2015, which means it's now payable through employerprovided health spending accounts.
"We've seen a little bit of an uptick in claims there," says Joan Weir, director of health and dental policy at the Canadian Life and Health Insurance Association.
While the issues around medical marijuana coverage have come up in member meetings and some insurers are putting exceptions in place when asked by plan sponsors, Weir says there isn't a lot of clamour from employers to add it to group benefits plans. "There are just enough questions about how we do it, does it actually make people more productive . . . . There are still questions about all of that. Right now, we're sort of watching."
Adam Greenblatt, co-founder and executive director of Santé Cannabis, Quebec's first medical marijuana clinic, says there's a big movement towards coverage, despite the drug bypassing many of the regulatory hurdles. "Medical marijuana has largely evolved in Canada because of court rulings," he says.
The industry at large relies on Health Canada guidelines when it comes to managing the dosage and pricing of pharmaceuticals and other medications. "Medical marijuana doesn't fit tidily into the current paradigm for prescription medication," says Karen Taylor Smith, senior manager for group benefits at the Benefits Trust.
"There is, from the medical community, information that there can be a very wide variation in dosing, depending on the individual patient and the condition that it's being used for, because there's a growing categorization of conditions where clinical studies are showing it's effective."
There's also some emerging data around the cost benefits, particularly when it comes to the substitution effect, "where people use marijuana in place of conventional medication that group benefits plans would happily pay for," says Greenblatt.
An example would be to compare the cost of marijuana to that of Zofran, a typical anti-nausea drug used for chemotherapy patients. Zofran costs $40 a pill, while a marijuana joint costs about $2 or $3. "You can start to get a sense of the costs," says Greenblatt.
But Weir questions the business case. "It's not clear yet that medical marijuana would necessarily replace other medication. While cost is only one part of the equation, insurers are looking for solid evidence that medical marijuana will not simply add cost to benefits plans.
"Are we making the employee more productive and/or enabling an employee on disability to return to work? Of course, the business case equation focuses on cost, and there are other considerations as well."
Murray, however, suggests the issue is fairly straightforward. "It is simple medicine and mathematics," he says. "In many cases, cannabis is a more cost-effective treatment for patients than the alternatives while also causing less harm. If a treatment is more cost-effective and results in patients getting back to work and healthier more quickly, it is a win for the insurance provider and the employer. Most importantly, it is a win for the patient."
The argument that medical marijuana is a cheaper option is a good reason for a benefits provider to be in favour of any legislation that requires it to cover the drug, according to Cascadden. "I think what's ultimately going to happen is that it will simply become properly administered by benefits providers and everything else.
"And I think we're going to end up in a place where we do have the producers being regulated, which is what the federal government was trying to do, and that will increase the legitimacy of it because then they can say this strain does X and this strain does Y. Once you know that, it will be a lot easier to regulate and there will be more precise costs associated with it."
Taboos and stigma linger
Despite the new government's stance on legalizing marijuana and the anecdotal evidence of its medical benefits, long-standing taboos associated with the drug persist.
"Part of that is because it's cannabis and part of it is just because it's a plant medicine," says Jamie Shaw, former president of the Canadian Association of Medical Cannabis Dispensaries. "There is stigma towards plant medicine in Canada as well that [isn't] cannabis."
Murray believes there's a knowledge gap rather than a stigma, so his organization actively engages with the health-care community. "We can overcome the knowledge gap by having open dialogue and by facilitating conversations and engaging in the evolving legislative process," he says.
Ultimately, advocates for the benefits of medical marijuana believe plans should cover it like any other pharmaceutical drug. "Most plans cover pharmaceuticals up to a certain percentage of the cost, depending on the plan, and we believe cannabis should be treated the same way," says Murray.
"The first step towards coverage, however, is to have cannabis added to the provincial formularies. If the provinces were to request the inclusion of cannabis in the common drug review, this would give the Canadian Agency for Drugs and Technologies in Health the opportunity to demonstrate what we believe to be a much more cost-effective solution for the provinces."
But many members of the benefits industry don't expect to see Health Canada hand out an identification number any time soon. "Some of the licensed producers say they are trying to do some of these clinical trials but they are a long way away from having a level of evidence that Health Canada would need," says Sullivan. "I don't think it would ever bypass that."
In the meantime, Canada can take notes and learn lessons from countries like the Netherlands, where drug plan coverage of medical marijuana is common, and U.S. states, such as Washington and Colorado.
"What we're seeing in Washington state, for example, is a recreational cannabis program that is rolling right over their state-authorized medical program, and they have had some great difficulties with that because it looks like they chose recreational over medicinal when they already had some pieces in place of a medical system," says Shaw, noting Colorado addressed the medical system before allowing for recreational sales.
"In some cases, it's being covered by some private insurance companies in these two states."
News Moderator: Katelyn Baker 420 MAGAZINE ®
Full Article: Medical Questions, Regulations Create Confusion For Medical Pot Coverage
Author: Jennifer Paterson
Contact: Benefits Canada
Photo Credit: Wikimedia Commons
Website: Benefits Canada
For nearly a decade, Zaid, 23, had been suffering from a chronic condition called new daily persistent headaches. He tried a variety of prescription medications and alternative treatments, but nothing really worked. "I turned to medical cannabis after I learned that it could work for my condition and it was really working well, but the cost started adding up," he says, noting his monthly out-ofpocket costs for vaporizing the drug were averaging about $800.
Zaid's benefits had covered the other prescription drugs and treatments he had tried to relieve his pain, whether they were through his father's employer-paid plan or his undergraduate health coverage at the University of Waterloo. He had even obtained quick approval for a few medications that weren't on the formulary.
"I approached the school to do the same thing with medical cannabis, but this time, it ended up being an eightmonth process of talking with the student union, lots of meetings and conversations about medical cannabis and its use, a lot of education," he says.
"In the end, they determined it would have a positive impact on both my health and my education, so the school decided to cover it."
Zaid is the founder and executive director of a group called Canadians for Fair Access to Medical Marijuana. "I am helping a lot of people through CFAMM's individualized insurance education program," he says.
"Patients are reaching out to their employers and to their group plan administrators to try to get coverage, and I think more and more employers are responding. We're just going through that process with a lot of them now. It's really a long process and people react with misconceptions surrounding it at first, so there's a lot of education needed in most cases."
Chris Murray, director of medical development at Bedrocan Canada Inc., one of nearly 30 licensed producers in Canada, says the body of evidence for the benefits of medical marijuana is growing and researchers are looking at cannabis more regularly now than they were a few decades ago. The company is working with Zaid to identify people who may be eligible for insurance based on their existing group benefits plans.
"We believe there are hundreds, if not thousands, of other Jonathans out there who just need the right guidance," he says. "Our hope is that a hands-on approach will create momentum and ultimately lead to system-wide changes."
If there are others like Zaid out there, plan sponsors will want to pay attention as there's a chance one of them works for their company. And with drug costs continuing to escalate and companies like Shoppers Drug Mart exploring the possibility of getting into the sale of medical marijuana, employers will want to keep an eye on this issue.
Keeping it legal
The legislative landscape around medical marijuana in Canada has changed dramatically in recent years. Canada is still dealing with the fallout of the most recent significant change that began in June 2013 when the marijuana for medical purposes regulations came into effect. The regulations, which allow licensed producers to grow and distribute medical marijuana, have been subject to numerous legal challenges, with the court recently having declared them invalid.
On the topic of legalizing marijuana for recreational purposes, federal Health Minister Jane Philpott announced in April the government would introduce legislation next year. "The election of the Liberal majority government in October and the legalization narrative was an enormous change in the equation," says Mike Sullivan, president of Cubic Health Inc.
"But with the recent decision by the appeals court that effectively suggested the new regulations are not appropriate, there was a messaging back saying that the new regulations implemented by the Conservative government don't work and they need to be fixed.
"It has left things in an enormous mess, and I don't think anybody knows what's going to happen now until the regulations get redrafted and recreated. [Legalization] is very much akin to something becoming over the counter in the prescription drug benefit world. If it becomes an over-the-counter product, why does anybody go through the process of obtaining a prescription and having it run through as a prescription?"
Another legislative issue that could affect employers is around discrimination, according to Will Cascadden, a partner at McCarthy Tétrault LLP's Calgary office.
"If a doctor tells an employee their illness requires treatment to be the use of medical marijuana in some form - and that's the medical prescription - and the employee says, 'If I needed insulin, it would be covered, but because I need medical marijuana, it isn't,' that could be discriminating against someone on the basis of illness or disability. "If group benefit plans don't cover it, I can see there being a challenge from a human rights' perspective. Ultimately, the humans rights [tribunals] will say it is discriminatory to not cover that medication, when you cover others, because that particular disability is the one a person has and if they're not getting the same treatment, that's discriminatory."
But the first step will have to be sorting out the regulatory regime, and then the pharmaceutical industry and benefits providers will have to figure out how to deal with it, he says. "At that point, there will be a process."
'Uptick in claims'
It's becoming more and more common for doctors to prescribe medical marijuana to people with certain types of cancer, HIV/AIDS, Crohn's disease and multiple sclerosis, as well as for chronic pain and as a sleep aid or a replacement for potentially expensive and harmful opioid treatments.
"Why are certain drugs covered and others not covered?" asks Robert Crowder, president of the Benefits Trust. "It's a real question that employers are battling with and it's becoming a bigger and bigger issue as the benefits of medical marijuana are becoming more and more relevant on a case-by-case basis."
While there are about 30 companies with licences to produce and sell medical marijuana in Canada, Health Canada hasn't provided it with a drug identification number. But the Canada Revenue Agency did add it as a medically exempt tax credit at the end of 2015, which means it's now payable through employerprovided health spending accounts.
"We've seen a little bit of an uptick in claims there," says Joan Weir, director of health and dental policy at the Canadian Life and Health Insurance Association.
While the issues around medical marijuana coverage have come up in member meetings and some insurers are putting exceptions in place when asked by plan sponsors, Weir says there isn't a lot of clamour from employers to add it to group benefits plans. "There are just enough questions about how we do it, does it actually make people more productive . . . . There are still questions about all of that. Right now, we're sort of watching."
Adam Greenblatt, co-founder and executive director of Santé Cannabis, Quebec's first medical marijuana clinic, says there's a big movement towards coverage, despite the drug bypassing many of the regulatory hurdles. "Medical marijuana has largely evolved in Canada because of court rulings," he says.
The industry at large relies on Health Canada guidelines when it comes to managing the dosage and pricing of pharmaceuticals and other medications. "Medical marijuana doesn't fit tidily into the current paradigm for prescription medication," says Karen Taylor Smith, senior manager for group benefits at the Benefits Trust.
"There is, from the medical community, information that there can be a very wide variation in dosing, depending on the individual patient and the condition that it's being used for, because there's a growing categorization of conditions where clinical studies are showing it's effective."
There's also some emerging data around the cost benefits, particularly when it comes to the substitution effect, "where people use marijuana in place of conventional medication that group benefits plans would happily pay for," says Greenblatt.
An example would be to compare the cost of marijuana to that of Zofran, a typical anti-nausea drug used for chemotherapy patients. Zofran costs $40 a pill, while a marijuana joint costs about $2 or $3. "You can start to get a sense of the costs," says Greenblatt.
But Weir questions the business case. "It's not clear yet that medical marijuana would necessarily replace other medication. While cost is only one part of the equation, insurers are looking for solid evidence that medical marijuana will not simply add cost to benefits plans.
"Are we making the employee more productive and/or enabling an employee on disability to return to work? Of course, the business case equation focuses on cost, and there are other considerations as well."
Murray, however, suggests the issue is fairly straightforward. "It is simple medicine and mathematics," he says. "In many cases, cannabis is a more cost-effective treatment for patients than the alternatives while also causing less harm. If a treatment is more cost-effective and results in patients getting back to work and healthier more quickly, it is a win for the insurance provider and the employer. Most importantly, it is a win for the patient."
The argument that medical marijuana is a cheaper option is a good reason for a benefits provider to be in favour of any legislation that requires it to cover the drug, according to Cascadden. "I think what's ultimately going to happen is that it will simply become properly administered by benefits providers and everything else.
"And I think we're going to end up in a place where we do have the producers being regulated, which is what the federal government was trying to do, and that will increase the legitimacy of it because then they can say this strain does X and this strain does Y. Once you know that, it will be a lot easier to regulate and there will be more precise costs associated with it."
Taboos and stigma linger
Despite the new government's stance on legalizing marijuana and the anecdotal evidence of its medical benefits, long-standing taboos associated with the drug persist.
"Part of that is because it's cannabis and part of it is just because it's a plant medicine," says Jamie Shaw, former president of the Canadian Association of Medical Cannabis Dispensaries. "There is stigma towards plant medicine in Canada as well that [isn't] cannabis."
Murray believes there's a knowledge gap rather than a stigma, so his organization actively engages with the health-care community. "We can overcome the knowledge gap by having open dialogue and by facilitating conversations and engaging in the evolving legislative process," he says.
Ultimately, advocates for the benefits of medical marijuana believe plans should cover it like any other pharmaceutical drug. "Most plans cover pharmaceuticals up to a certain percentage of the cost, depending on the plan, and we believe cannabis should be treated the same way," says Murray.
"The first step towards coverage, however, is to have cannabis added to the provincial formularies. If the provinces were to request the inclusion of cannabis in the common drug review, this would give the Canadian Agency for Drugs and Technologies in Health the opportunity to demonstrate what we believe to be a much more cost-effective solution for the provinces."
But many members of the benefits industry don't expect to see Health Canada hand out an identification number any time soon. "Some of the licensed producers say they are trying to do some of these clinical trials but they are a long way away from having a level of evidence that Health Canada would need," says Sullivan. "I don't think it would ever bypass that."
In the meantime, Canada can take notes and learn lessons from countries like the Netherlands, where drug plan coverage of medical marijuana is common, and U.S. states, such as Washington and Colorado.
"What we're seeing in Washington state, for example, is a recreational cannabis program that is rolling right over their state-authorized medical program, and they have had some great difficulties with that because it looks like they chose recreational over medicinal when they already had some pieces in place of a medical system," says Shaw, noting Colorado addressed the medical system before allowing for recreational sales.
"In some cases, it's being covered by some private insurance companies in these two states."
News Moderator: Katelyn Baker 420 MAGAZINE ®
Full Article: Medical Questions, Regulations Create Confusion For Medical Pot Coverage
Author: Jennifer Paterson
Contact: Benefits Canada
Photo Credit: Wikimedia Commons
Website: Benefits Canada
